EHU067921
MISSION® esiRNA
targeting human TRIM22
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.51
UNSPSC Code:
41105324
description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
CCGAGCTCCTGAGTGTTCTCATTCCTTTACCCACTTCTGCATAGTAGCCCTTGTGCTGAGACTCAGATTCTGCACCTGAGTTCATCTCTACTGAGACCATCTCTTCCTTTCTTTCCCCTTCTTTTACTTAGAATGTCTTTGTATTCATTTGCTAGGGCTTCCATAGCAAAGCATCATAGATTGCTGATTTAAACTGTAATTGTATTGCCGTACTGTGGGCTGGAAATCCCAAATCTAGATTCCAGCAGAGTTGGTTCTTTCTGAGGTCTGCAAGGAAGGGCTCTGTTCCATGCCTCTCTCCTTGGCTTGTAGAAGGCATCTTGTCCCTATGACTCTTCACATTGTCTTTATGTACATCTCTGTGCCCAAGTTTTCCCTTTTTATTAAGACACCAGTCATACTGGCTCAGGGCC
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... TRIM22(10346)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Li Liu et al.
Oncotarget, 8(37), 62069-62080 (2017-10-06)
Expression pattern and biological roles of TRIM22 remains unknown in most human cancers. The present study aims to discover its clinical significance and function in human non-small cell lung cancer (NSCLC). Immunohistochemistry was used to examine TRIM22 expression in 126
Chen Yang et al.
Cellular & molecular immunology, 13(1), 94-102 (2015-02-17)
TRIM22, a tripartite-motif (TRIM) protein, is upregulated upon interferon alpha (IFNα) administration to hepatitis C virus (HCV)-infected patients. However, the physiological role of TRIM22 upregulation remains unclear. Here, we describe a potential antiviral function of TRIM22's targeting of the HCV
Global Trade Item Number
| SKU | GTIN |
|---|---|
| EHU067921-20UG | 04061828617463 |
| EHU067921-50UG | 04061828385362 |